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INTRODUCTION
over the past thirty years, numerous studies have
attempted to determine whether Type A behavior (TAB) is a
risk factor for coronary heart disease (CHO; see BoothKewley & Friedman, 1987).

TAB has been defined as a pattern

of behaviors including "extremes of competitive achievement
striving, hostility, aggressiveness, and a sense of time
urgency, evidenced by vigorous voice and psychomotor
mannerisms" (Matthews, 1988).

Type B's are individuals who

do not display the characteristics of Type A's.
Contradictory findings in research on TAB and CHO have
spurred so much debate that Dimsdale (1988) has suggested
the 'A' in TAB might well stand for acrimony.

The purpose

of this dissertation is to identify the study
characteristics associated with positive and null findings.
At the heart of the debate over inconsistent findings
in research on TAB and CHD is the failure of recent studies
to replicate the findings of previous research.

Before

1978, the findings from a number of studies converged in
suggesting that TAB is a risk factor for CHD.

In fact, the

evidence in 1978 was sufficiently convincing that a review
panel from the National Heart, Lung and Blood Institute
(NHLBI) concluded that TAB is a risk factor for CHD of equal
magnitude to the traditional risk factors (smoking, serum
cholesterol, and blood pressure).

1

Suddenly after the NHLBI panel's findings were
published, Type A's no longer seemed to be at greater risk
for CHO.

In contrast to the consistent and strong

relationship reported prior to 1978, a remarkable number of
subsequent studies failed to find an association between TAB
and CHO (for reviews, see Booth-Kewley, 1987; Matthews,
1988).

The trend towards null findings has been so

consistent that the participants of the 1987 annual meeting
of the Psychosomatic Society questioned the relevance of the
whole Type A concept (Staff, 1987).
Perhaps the most disconcerting evidence has been the
results of Ragland and Brand's (1988a,b) twenty-two year
follow-up study; this study was based on subjects who
participated in the first prospective study to report an
association between TAB and CHO.

Ragland and Brand (1988a)

reported that Type B's with prior CHO incurred a second
fatal myocardial infarction (MI) in less time than Type A's.
Furthermore, healthy Type A's were no more likely than Type
B's to incur a fatal MI (Ragland & Brand, 1988b).

To the

chagrin of many researchers (Correspondence, 1988), these
results were interpreted by some as suggesting that TAB is
not a risk factor for CHO.
However, not all of the recent research has
contradicted earlier findings.

One true experimental study

successfully reduced the number of subsequent episodes of
CHO in a treatment condition that was designed to modify TAB
2

(Friedman et al., 1986).

These results suggest TAB produces

CHO.
The research discussed in the current dissertation
attempts to identify some of the reasons for the confusing
results in research on TAB and CHO by a quantitative review
of the literature.

The first chapter introduces a Decision

Theory (OT) model that can be used to define subject
selection biases that may have occurred in research on TAB
and CHO.

The OT model is used to develop hypotheses

concerned with how subject selection biases can influence
the results of a study.

The second chapter discusses the

methods used in the quantitative review and a third chapter
discusses the results.

The results lend support to the

value of the OT model by suggesting that a type of subject
selection bias referred to as diseased based spectrum (DBS)
bias has produced some of the null findings in recent
studies.

The fourth chapter discusses the implications of

the results for future research on TAB and CHO.

The final

chapter discusses general implications of the OT model for
future research.

This chapter illustrates how another

subject selection bias (mortality bias) can be described by
the OT model.

In addition, a formula is presented for

estimating the reduction in correlation between TAB and CHO
in a study that is vulnerable to DBS bias.

3

A DECISION THEORY (OT) MODEL OF SUBJECT SELECTION BIASES
study Designs Used in Research on TAB and CHD
Before discussing the DT model, the following section
reviews the different types of study designs used in
research on TAB and CHD.

A major purpose of the research

described in this dissertation is to determine how subject
selection biases influence the magnitude of the relationship
between TAB and CHD.
selection procedures.

study design determines subject
Therefore, clear and explicit

categories of study design based on the method of subject
selection are necessary for assessing the influence of
subject selection on the results of research on TAB and CHD.
The most frequently used study designs in research on
TAB and CHD have included (a) recurrent CHD studies, (b)
angiography studies, (c) studies that select patients on the
basis of their risk factor status, (d) population studies,
(e) case-control studies and (f) healthy population
prospective studies.

These study designs have been referred

to as epidemiological study designs because these types of
study designs have frequently been employed in
epidemiological research.

These study designs vary in how

subjects are selected by whether the design is (a) high risk
or healthy population, (b) cross-sectional or prospective
designs and (c) the method used to recruit subjects.
For the current paper, the phrase "high risk" study
design refers to a study design in which only subjects with
4

at least some disease are selected for study.

Therefore,

only a part of the full range of disease severity is
examined in high risk studies 1 •

In contrast, "healthy

population" studies sample subjects across the full spectrum
of disease.

In particular, study designs are considered to

be "high risk" if a comparison group includes individuals
with substantial disease.

These comparison groups with

substantial disease are referred to as high risk comparison
groups.

Alternatively, comparison groups that include

individuals who are healthy are referred to as healthy
comparison groups.

Studies that use healthy comparison

groups are referred to as healthy population studies.
Research on TAB and CHO has used three types of high
risk study designs: (a) angiography studies, (b) recurrent
CHO studies and (c) studies that select subjects on the
basis of their risk factor status.

Healthy population

studies include the following study designs: (a) healthy
population prospective studies, (b) case-control studies and
(c) cross-sectional population studies.
In recurrent CHO studies, subjects are selected who
have incurred a MI; these subjects are followed over time to
determine which subjects develop recurrent CHO.

Individuals

with a previous MI who do not develop future CHO (a high
risk comparison group) are compared with individuals who
develop recurrent CHO in the future (a diseased group).
Researchers have expected that a higher percentage of
5

individuals with recurrent CHO should be Type A than
individuals who do not experience recurrent CHO.

Recurrent

CHD studies constitute a high risk study design.
A second type of high risk study is an angiography
study.

An angiography is a diagnostic test that is used to

determine the extent of a patient's coronary artery disease
(CAD); CAD is a precursor to most cases of MI.

In research

on TAB, individuals who are diagnosed by the results of an
angiography as having clinically relevant CAD are compared
with subjects who are diagnosed as having less CAD.
Researchers have expected that a higher proportion of the
diseased group would be Type A than the high risk comparison
group.
An angiography study is a type of "high risk" study
because the comparison group includes many individuals with
CAD.

Diagnostic screening procedures (e.g., stress testing)

insure that most patients undergoing diagnostic coronary
angiography have substantially more CAD than healthy
individuals.

Therefore, almost all subjects who undergo

angiography have substantial CAD.

This fact may account for

why researchers have found only minimal differences in the
degree of disease severity found in comparison and diseased
groups in angiography studies (Fried & Pearson, 1987).
Some studies selected subjects on the basis of their
risk factor status; these studies only select subjects who
are considered to be at high risk for future CHD.
6

The

subjects in these studies are at high risk for future CHO
because they possess some known risk factor (e.g., serum
cholesterol) for CHO.

The comparison groups in these

studies frequently include subjects with subclinical disease
produced by the presence of traditional risk factors.

Thus,

a study that selects subjects on the basis of their risk
factor status is a type of high risk study.
There are two types of healthy population studies: (a)
population studies and (b) case control studies.

In

population studies, subjects are sampled from community
populations (e.g., towns or a factory).

For healthy

population studies, subjects without CHO are compared with
subjects with CHO who live in the same population.

In case

control studies, individuals with CHO are selected from
hospital(s) or physician(s) practices.

Healthy individuals

are selected from the same population as the individuals
with CHO.

For example, some case control studies have used

patients in the same hospital without CHO as control
subjects.
In prospective studies, subjects are selected on the
basis of their disease status, and they are followed over
time to determine which alleged risk factors predict future
disease.

In cross-sectional studies, individuals are

assessed at a single point in time.
Recurrent CHO and healthy population prospective
studies are specific types of prospective studies.
7

For

healthy population prospective studies, only healthy
individuals are initially selected for study.

Population

studies, case-control studies and angiography studies are
types of cross-sectional studies.

Studies that select

subjects on the basis of their risk factor status may be
cross-sectional or prospective.
Studies have recruited subjects with CHD by four
methods: (a) selection on the basis of risk factor status,
(b) selection by the results of an angiography in which
subjects were diagnosed as having clinically significant
CAD, (c) selection because the individual developed CHD
during the course of a prospective study and (d) selection
because the subject worked in a company or town
participating in a study.

Studies have either recruited

healthy subjects from (a) specific populations (e.g, towns,
communities, patients in hospitals without CHD disease) or
(b) used volunteers.
A Decision Theory CDT) Model for Describing Subject
Selection Biases
The need for a statistical model.

All of the different

types of study designs used in research on TAB and CHD are
vulnerable to subject selection biases.

However, not all

designs are vulnerable to the same biases.

The degree to

which the various subject selection biases influence
research on TAB and CHD is unknown.

Thus, the magnitude of

the association between TAB and CHD found in any given study
8

may be biased by subject selection biases (Matthews, 1988).
Therefore, there is a great deal of confusion regarding the
interpretation of results in research on TAB and CHO
(Dimsdale, 1988).
Researchers can test hypotheses concerning how subject
selection biases by examining how the magnitude of the
association between TAB and CHO varies across different
study designs.

Thus, determining the extent to which

subject selection biases have contributed to different
findings in research on TAB and CHO has implications for the
types of study designs that are employed in future research
and how the results of research on TAB and CHD is
interpreted.
The study designs used in research on TAB and CHD are
vulnerable to two types of subject selection biases: (a)
spectrum and (b) selection biases.

Research suggests

spectrum and selection biases have led to a number of
confusing and contradictory findings in epidemiological
research (Ransohoff & Feinstein, 1978).
Given that biases are an important problem in
epidemiological research, a general strategy for defining
and testing for such biases would be useful.

The

differences between spectrum and selection bias become
clearer when a statistical model is used to define these
biases.

Decision Theory (DT) is a statistical model that

can be used to define spectrum and selection biases (Miller
9

et al., 1988).

The following paragraphs describe the OT

model introduced in Miller et al.

This OT model is then

used to develop hypotheses to detect the presence of
spectrum and selection biases in research on TAB and CHO.
In addition, the OT model can be used to develop hypotheses
regarding which biases influence each type of study design.
The OT model.

Figure l(a) illustrates the results of a

hypothetical healthy population study of the relationship
between TAB and CHO in terms of the OT model.

The x-axis

represents a continuum of the degree of CHO in the sample.
Higher values indicate greater severity of CHO.

Negative

values on the x-axis represent the healthy range and
positive values represent the diseased range.

The y-axis

indicates the frequency of individuals at each level across
the full spectrum of CHO.
The cutpoint labeled Q in Figure l(a) is used to
distinguish healthy individuals from individuals with CHO.
The

indicates the point at which CHO is sufficiently

Q

severe that some evidence of CHO (i.e., MI or angina) is
present.

Of course, no exact point exists at which CHO is

universally expressed.

The Q value only represents a mean

value.
One of the two frequency distributions illustrated in
Figure l(a) represents all Type A's in the hypothetical
study sample and the other distribution represents all Type
B's.

The OT model illustrated in Figure 1 assumes Type A's
10

Figure 1
A Decision Theory Model of DBS and Mortality Bias

d'
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develop CHD more frequently than Type B's.

Thus, the

frequency distribution associated with more CHD represents
individuals who are Type A's and the distribution associated
with less CHD represents individuals who are Type B's 2 •

The

frequency distribution of Type A's is the same magnitude as
the Type B distribution because prior research suggests that
healthy populations include equal numbers of Type A's and
B's (see Miller et al., 1988).
Assessment of statistical association.

The effect size

(g') illustrated in Figure l(a) is an indicator of the

degree of statistical association and represents the
standardized mean difference in degree of disease between
the two distributions of individuals with and without the
risk factor (Glass, Smith & McGraw, 1981).

In Figure l(a),

g' represents the standardized mean difference in degree of
CHD between the Type A's and Type B's.

However, this method

of assessing statistical association in research on TAB and
CHD has not been used.

Instead, researchers have analyzed

their results by contingency tables.
A contingency table can be used to describe the degree
of statistical association between TAB and CHD in the
hypothetical study sample illustrated in Figure l(a).

The

frequency distributions can be arranged into the four groups
in the contingency table presented in Table 1.

In this

table, Type B's with CHD are referred to as false negatives
(FN) because CHD is not expected to be present.
12

Healthy

Table 1
A,_Contingency Table of Disease versus Risk Factor Status
Disease Status
Coq:>arison Group

Risk Type A's
factor
status
Type B's

Diseased Group

False
Positives CFP)

True
Positives (TP)

True
Negatives CTN)

False
Negatives (FN)

Relative Risk (RR) = CTP)(TN

+

FN)/(FP

+

TP)(FN)

Odds ratio = (TP)(TN)/(FP)(FN)
TP

Sensitivity

= ----------

CTP + FN)

TN

Specificity

= ----------(FP

+

TN)

13

Type A's are ref erred to as false positives (FP) .

Type A's

with CHO are ref erred to as true positives (TP) and healthy
Type B's are ref erred to as true negatives (TN).
Two indices--the sensitivity and the specif icity--have
been used to describe the relation between TAB and CHO.

The

sensitivity indicates the degree to which TAB can identify
individuals with CHO in the diseased group.

For example,

69% of the subjects who developed CHO were Type A's in the
Western Collaborative Group Study (WCGS; Rosenman, Brand,
Jenkins, Friedman, Straus, & Wurm, 1975).

The WCGS was the

first prospective study that examined the relationship
between TAB and CHO.

Therefore, the sensitivity in the WCGS

study is 69%.
The specificity is estimated with data from the
comparison group.

The percentage of healthy subjects who do

not possess the risk factor (i.e., Type B's) in the
subsample is referred to as the specificity.

The

specificity indicates the degree to which the absence of the
risk factor is associated with the absence of the disease.
For example, the specificity of TAB was 52% in the WCGS
because 52% of the individuals who remained healthy in that
study were Type B's.

High values of sensitivity and

specificity indicate there is a strong association between
the risk factor and the disease.
Two indices have been used in research on CHO to
indicate the degree of statistical association present in
14

Table 1.

The relative risk (RR) is an index that indicates

the increased risk for CHO associated with the pre$ence of
TAB in a prospec.ti ve study.

In research on TAB and CHO, the

RR represents the increased odds of Type A's developing CHO
compared with Type B's.

A slightly different statistic--the

odds ratio--is used for cross-sectional studies.

The

formulas for these two types of risk ratios are presented at
the bottom of Table 1.

Risk ratio indices indicate rate of

change just as the slope in a regression equation indicates
rate of change.
The chi-squared test is used to determine whether the
association between TAB and CHO in the contingency table is
statistically significant.

The magnitude of the chi-squared

statistic is influenced by both the sensitivity and the
specificity.

That is, larger values of the chi-squared

statistic are associated with higher risk ratios.
Disease Based Spectrum COBS) Bias in High Risk Studies
Spectrum bias is synonymous with range restriction.
That is, spectrum bias is present when the variability on
one variable is restricted so that the correlation between
the variable with other variables is different than it would
be if the entire range of values on the variable were
examined.

DBS bias occurs when disease status is used to

select subjects for study independently of their risk factor
status (Miller et al., 1988).

When subjects are selected in

this manner, the range of disease in the sample is
15

restricted.

For example, the level of disease severity may

not vary greatly between the high risk comparison group and
diseased group if only individuals with severe disease are
selected for study.

This narrow spectrum of disease in the

study sample may decrease any existing differences between
the percentage of Type A's found in a high risk comparison
group and a diseased group.
DBS bias may occur frequently in high risk studies.
For example, Miller, Turner, Tindale and Posavac (1988)
found evidence to suggest that the narrow spectrum of
disease severity in angiography studies reduces correlations
between TAB and CAD.

Therefore, researchers may find no

relation between TAB and CHD in high risk studies and
falsely conclude that there is no relation between TAB and
CHD.
Figure l(b) can be used to describe DBS bias in terms
of the DT model and to illustrate how DBS bias reduces
statistical associations in high risk studies.

For example,

Figure l(b) could represent the relation between TAB and CHO
in a recurrent CHD study.

The point labeled £' in Figure

l(b) represents the point at which individuals who have
already incurred a MI develop sufficient CHD to incur
recurrent CHD (angina or a second MI).

A comparison of

Figure l(a) and (b) can be used to illustrate the difference
between healthy population and recurrent CHD studies.
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The spectrum of CHO in the high risk comparison group
is attenuated in Figure l(b).

That is, the range of values

on the x-axis is decreased in the recurrent CHO study.
similarly, other types of high risk studies exclude most
healthy individuals from the study.

Therefore, Figure l(b)

illustrates a situation that occurs in all types of high
risk studies.
For the healthy population studies described in Figure
l(a), more Type B's than Type A's are present in the healthy
range of individuals.

Recall that the healthy and diseased

range of individuals is defined by the Q.

Thus, the

individuals with low negative scores on the x-axis represent
healthy individuals included in healthy population
comparison groups.
Only individuals between Q and Q' are included in the
high risk comparison groups used in recurrent CHO studies.
For high risk studies, the specificity is estimated as the
percentage of the sample located between Q and Q' that is
Type B.

More Type A's than B's are included in this range

of the continuum of CHO.

Subjects from the healthy end of

the CHO continuum--where more Type B's are present--are
excluded from recurrent CHO studies.

Therefore, the

specificity found in high risk studies is generally much
lower than the specificity found in healthy population
studies (Miller et al., 1988).

The high percentage of Type

A's found among those subjects in the high risk comparison
17

group lowers the specificity and the value of the chisquared statistic.

Therefore, high risk studies may find

only a small association between TAB and CHO even when a
strong relationship exists in the entire population.
An example may help to illustrate the degree to which
DBS bias can attenuate statistical associations in high risk
studies.

Table 2 illustrates the healthy population and

recurrent CHO study findings of the WCGS.

For the healthy

population results, the specificity (49%) is adequate and
the study reported a statistically significant chi-squared
statistic between TAB and CHO and the RR was 2.5.

The

specificity in the recurrent CHO study is much lower (30%),
the relation between TAB and recurrent CHO is not
statistically significant, and the RR is smaller (RR= 1.1).
Selection Biases
Selection bias is defined as occurring when the
"subjects' status on a hypothesized risk factor and the
disease jointly determine which subjects are selected into
the study" (Miller et al., 1988).

That is, some third

variable that is correlated with both the risk factor and
the disease is used to select subjects.
For the current paper, one type of selection bias is
used to illustrate how the OT model can be used to describe
selection biases.
bias.

This selection bias is referred to as age

Age bias is defined as occurring in research on TAB

and CHO when TAB and CHO status jointly determine which
18

Table 2
Description of the WCGS at the 4.5 year follow-up
(a) Healthy population prospective results
Heal thy
I
Diseased
I
Total
--------------------------------!------------------------- --------------Type A

15n

52

1598

Type B

1532

21

1584

Total

3109

73

3182

Percentage diseased = 2.3
Sensitivity = 71
Specificity = 49
RR = 2.5

d' = .373

Chi-squared test= 11.19 p

<

.0001

Cb) Actual results for the recurrent CHO study of the WCGS at 4.5 years.
Without Recurrent Disease
I With Recurrent Disease
Total
--------------------------------1------------------------- ---------------1
Type A
114
I
23
137
I
--------------------------------!------------------------- -------------1
Type B
56
I
10
66
I

--------------------------------!------------------------- --------------

Total

170

Estimated results
Sensitivity
Specificity
RR = 1.2
Chi-squared

= 75%
= 30%
d' = .37
= p > .05

1

I
I

33

203

Actual results
Sensitivity =
Specificity =
RR= 1.1 d'
Chi-squared=

19

70
33

= .14
p > .05

subjects are included in the study sample as a function of
the age of the study sample.

For the current paper, an

example of how age bias could occur in research on TAB and
CHD was used to illustrate how age bias can alter the
magnitude of associations between risk factors and diseases.
The DT model in Figure 2 can be used to describe age
bias.

Figure 2 illustrates how the percentage of Type A's

and B's with CHD changes the sensitivity and degree of
statistical association between TAB and CHD for the same men
when they are examined at different ages in a healthy
population prospective study.
Figure 2 illustrates the development of CHD in a
hypothetical sample of men who all eventually develop CHD.
The degree of CHD in the sample is illustrated when the men
are 40, 50 and 60 years old.

Over half the sample has CHD

when the patients are 60 years old.

In contrast, less than

a quarter of the individuals have CHD when the subjects are
40 years old.
The percentage of individuals with CHD who are Type A's
varies with each age group.

For the forty year olds, most

of the individuals with CHD are Type A's.
sensitivity is very high.

Thus, the

The new cases of CHD at age 50

and 60 are the subjects that represented in the section of
the distribution that is defined by £ as healthy at age 40
but are defined as having CHD at age 50 (see Figure 2).

20

In

Figure 2
A DT Model of a Prospective Study
c
Sample at age

40

Sample at age

50

Sample at age

60

-3

-2

-1

healthy
subjects

Notes.

0

1

2

diseased
subjects

As in Figure 1, the distribution with more CHD

represents Type A's, the distribution with less CHD
represents Type B's and the x-axis indicates the severity of
CHD.
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the 50 year old group, a higher percentage of Type B's have
developed CHD.

Finally, more of the individuals who

developed CHD after they were 50 are Type B's than Type A's.
Figure 2 illustrates that most Type A's will incur CHD
when they are younger than Type B's.

Therefore, one would

expect that most Type A's would be younger than Type B's who
are selected for recurrent CHD studies.

Individuals who

develop CHD when they are younger tend to have less severe
CHD than individuals who develop CHD when they are older.
These younger and hardier individuals with CHD may survive
longer after their initial MI and not die within the time
frame of the recurrent CHD study.

Therefore, one may find

an inverse association between TAB and recurrent MI.
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A REVIEW OF EXPLANATIONS FOR NULL FINDINGS
Hypotheses Proposed by Previous Researchers
At present, "no entirely satisfactory explanation for
these null findings has been proposed (Dimsdale, 1988;
Matthews, 1988).

Several hypotheses have been forwarded.

The current section frames these hypotheses in terms of the
DT model.
Diseased based spectrum (DBS) bias.

Matthews (1988)

provided one clue to a possible explanation.

She noted that

most of the null findings have occurred in high risk
studies.

In support of her hypothesis, Miller et al.

(1988) found evidence suggesting that DBS bias has produced

the null findings in research on TAB in angiography studies.
Perhaps, DBS bias accounts for some of the confusion in
research on TAB and CHD.
DBS bias.

That is, high risk studies have

Therefore, high risk studies find null results

because DBS bias attenuates correlations between TAB and CHD
in these studies.

In contrast, studies not vulnerable to

DBS bias find positive results.
Selection bias.

There are other possible explanations

for the trend towards null findings in research on TAB and
CHD.

The study designs that have been used in research on

TAB and CHD are vulnerable to a number of different types of
selection biases (Matthews, 1988).
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Thus, the method used to

select subjects may be associated with the magnitude of the

g' between TAB and CHO.
Several third variables have been implicated in
research on TAB and CHO.

For example, some (e.g., Rosenman,

1986) have suggested that the culture or sex of the study
population may mediate the strength of the relationship
between TAB and CHO.
Insufficient sample size.

Booth-Kewley and Friedman

(1987) proposed another plausible explanation for the null
findings.

Their research suggests the null findings may

have occurred because the correlation between TAB and CHO is
low.

That is, some studies may have used a small sample

size that lacked sufficient statistical power to detect the
presence of the low correlation between TAB and CHO.
Disease criteria.

The location of the £ can influence

the strength of the association between two variables
(Rorer, Hoffman, & Hsieh, 1966).
criteria has a different g.

Each different disease

Therefore, different disease

criteria may influence the magnitude of the relation between
TAB and CHO.

In fact, Miller et al.

(1988) reported

evidence suggesting that different methods of defining CAD
influence the magnitude of the relation between TAB and CAD.
Indicator of TAB.

Many researchers (e.g., Rosenman,

1986; Williams et al., 1988) have suggested that the
magnitude of the relationship between TAB and CHO may vary
for different measures of TAB.
24

In terms of the DT model,

the g' between a measure of TAB and CHO may vary for
different measures of TAB.
The current Research
The current research attempts to identify the study
characteristics (i.e., high risk studies, method used to
select subjects, sample sizes, culture, sex, disease
criteria, indicator of TAB) that are associated with null
findings by a quantitative review.

In addition, reanalyses

of some studies are conducted to test whether the signs of
DBS bias identified by Miller et al. (1988) are present in
all types of high risk studies.

The presence of these signs

would suggest that DBS bias has produced the null findings
in high risk studies.
The current research is theoretically important because
a OT model is developed and tested that can be used to
identify subject selection biases in research on TAB and
CHO.

In addition, the current research attempts to identify

study design characteristics that play an important role in
mediating the strength of the relationship between TAB and
CHO.

These mediating variables may have important

theoretical implications for understanding why TAB has been
found to be associated with CHO in some studies.
The current research also has practical significance.
The identification of the study design characteristics that
mediate the relationship between TAB and CHO may lead to an
increased understanding of the reasons for the trend towards
25

null findings.

In addition, subject selection biases may

produce misleading results.

The current research attempts

to identify study designs that lead to misleading findings.
Therefore, the current research has implications for the
types of study designs that future researchers can use to
obtain the less biased estimates of the magnitude of the
relationship between TAB and CHD.
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METHOD
Locating Studies
Most of the studies included in the current review have
been used in previous reviews (Booth-Kewley and Friedman,
1987; Matthews, 1988; Miller et al., 1988).

Additional

articles were found using Booth-Kewley and Friedman's (1987)
procedures for locating studies.

Briefly, these procedures

include searching through journals that have published known
articles and using computerized searches such as
Psychological Abstracts and Medicus Indicus to find new
articles.

An attempt was made to include all studies that

were published before 1989.

Appendix A includes a list of

new articles presented in neither Booth-Kewley and
Friedman's, Miller et al.'s nor Matthews' reviews.
Criteria for Including Articles
Study selection criteria.

Studies were included in the

current review only if an article reported an attempt to
find a statistical relation between CHO and some measure of
TAB.

In addition, the current review was limited to

articles published in the English language.

For the current

research, only used at one of three types of indicators of
CHO were used in the current study:

(a) MI,

(b) MI or angina

(this category is referred to as CHO for the remainder of
this paper) or (c) CAD from the results of an angiography.
This selection criteria for CHO is slightly narrower than
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the criteria used by Booth-Kewley and Friedman (1987).

In

contrast, to Booth-Kewley and Friedman, studies that
assessed CHO by infrequently used disease outcomes were not
included in the current review.

For example, only a few

studies (see Booth-Kewley & Friedman, 1987) have used angina
as a disease outcome.

For such studies, insufficient data

were available to perform the detailed reanalyses and
comparisons across different study designs conducted in the
current review.
Similarly, an insufficient number of studies were
available to examine other psychological predictors of CHO
(e.g., hostility, depression or subcomponents of TAB such as
time urgency).

Thus, studies that only used these predictor

variables were not included in the current review.
The Friedman et al.

(1986) true experimental study

(Brackett & Powell, 1988) is not included in the current
review.

This report collapsed results across a treatment

and control group.

This analysis strategy is inappropriate

because the treatment successfully modified TAB.

Therefore,

collapsing across treatment and control conditions confounds
the results.
In addition, the results of one study (Williams et al.,
1988) were not included because this study was a follow-up
of the Williams et al.
study.

(1980) study and not an independent

The findings of the earlier study were used because

28

a correlation coefficient

(~)

could be calculated from the

1980 report and not from the 1988 report.
Finally, three studies (Friedman & Rosenman, 1959;
Rosenman & Friedman, 1961; Schwertner, Troxler, Uhl, &
Jackson, 1984) selected extreme Type A's and B's for study.
selecting extreme groups is a useful method to insure that
the constructs of interest are represented in the sample.
However, selecting extreme groups also increases the
magnitude of the

~

between the two variables.

three studies found the largest

~·s

In fact, all

between TAB and CHO of

any of the studies included in the current review.

Thus,

the results of these studies support the hypothesis that TAB
is associated with CHO.

However, the

~·s

for these studies

are not comparable with other studies and so the results of
these studies were not included in the current review.
Selection criteria for prevalence estimates.

The sex

or age composition of the sample may mediate the strength of
association between TAB and CAD (Rosenman, 1986).

To avoid

the problem of confounding results for sex and age, the
current research only used prevalence estimates of TAB from
studies of middle-aged men.
Selection criteria for studies used to test for the
presence of DBS bias.

The current research only tested for

signs of DBS bias in studies that assessed TAB by the SI.
There were two reasons why only these studies were examined.
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First, the SI is the measure of TAB that is the most highly
associated with CHD (Booth-Kewley & Friedman, 1987).
Second, only studies that assessed TAB by the SI
presented their results in sufficient detail for reanalysis.
The SI has often been treated as a dichotomous variable.
Therefore, the results have been presented in contingency
tables that yield sufficient information for reanalysis.

In

contrast, most studies that used self-report measures of TAB
have typically reported their results only in terms of tests
of significance that provide insufficient information for
reanalysis.
Statistical Analyses
Use of biserial and tetrachoric r coefficients.
current review, the correlation coefficient
the indicator of effect size.

The

~

(~)

In the

was used as

was used so as to allow

comparison with other meta-analyses of research on TAB and
CHD that

used~

to indicate the effect size (e.g., Booth-

Kewley & Friedman, 1987).

The

Pearson~

underestimates the

degree of association between two variables when the base
rate for an artifactually constructed dichotomous variable
is low (see Cohen & Cohen, 1984; Hunter, Schmidt & Jackson,
1982; Kemsey, Dunlap & Griffeth, 1988).

Both TAB and CHD

are artifactually constructed dichotomous variables.

In

prospective and population studies, the base rate for CHO is
low.

Therefore, the magnitude of the Pearson

~

between TAB

and CHD would vary with type of study design even if the
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magnitude of the actual
with study design.

~

between TAB and CHO does not vary

To avoid the base rate problem, biserial

and tetrachoric r's were calculated from the results
reported in the original studies.

The magnitude of these

coefficients is not influenced by the base rate.

The

biserial coefficient is used when one variable is
dichotomous and one variable is continuous.

The tetrachoric

coefficient is used when both variables are dichotomous.
Controlling for sampling variability.
~

A weighted mean

(WMR) was estimated by multiplying each individual study

~

by the study sample size and taking the average of the
Matthews (1988) and others (e.g., Hedges & Olkin,

products.

1985; Hunter et al., 1982) have argued that the weighted
mean is more appropriate than an unweighted mean as an
indicator of the average effect size across a series of
studies.

The WMR adjusts for the sampling variability

produced by studies of different sample sizes.

Sampling

variability could be a severe problem in the current
research because sample sizes varied from 25 to 11,364.
Methods used to sum r's.

Eleven studies reported null

results with no specific information that could be used to
calculate an

~·

As recommended by meta-analysts (Hedges &

Olkin, 1985),

the~

these cases.

To compute WMR's,

Fisher

~·s,

was considered to be equal to zero in
~·s

were transformed to

weighted by study sample size and then

transformed back into the~ metric3 •
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Testing for inter-study variability.

An inter-study

variation index (IVI; Hunter et al., 1982) was used in the
current research. to ascertain the homogeneity of summed
study effect sizes.

The IVI is an index of the percentage

of inter-study variation in study

~

that is beyond the

amount explained by sampling variability.

A large IVI

suggests that the studies are not comparable and the
magnitude of the WMR may be misleading.
Study Variables
Disease criteria.

Four different disease outcomes were

examined in the current review: (a) CHD, (b) MI, (c) CAD and
(d) fatal MI.

In addition, the CAD category was divided

into several subcategories according to the CAD scoring
method; these subcategories for CAD were used because
different CAD scoring methods appear to have a small
influence on the magnitude of the

~

between TAB and CAD (see

Miller et al., 1988).
Measures of TAB.

Measures of TAB were divided into

three categories: (a) the structured interview (SI;
Rosenman, 1978), (b) the Jenkins Activity Survey (JAS;
Jenkins, Zyzanski, & Rosenman, 1971) and (c) other selfreport measures.

The JAS has been used in a sufficient

number of studies to compare results across different study
designs.

Therefore, studies using the JAS are considered

separately from other less frequently used self-report
measures.
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study design.

Every study was classified as either a

cross-sectional or prospective design, and as either a
healthy population or high risk design based on the
definitions presented in the review section.

In addition,

study designs were classified according to how subjects were
recruited for study.
Culture.

The prevalence of TAB appears to be related

to culture (Rosenman, 1986).

Therefore, the results were

examined separately for studies conducted within the United
States and studies conducted in other countries.
Sex.

The sex of the subject may mediate the strength

of the relationship between TAB and CHD because sex is
correlated with both TAB (Rosenman, 1986) and CHD.

Although

most studies only examined men, some studies included women.
For studies reporting results for men and women separately,
only the results for men were used when summing
calculate WMR's.

~·s

to

In studies that only reported combined

results for both men and women, the percentage of the sample
that was female was recorded and an attempt was made to
determine if the percentage of females in these studies was
correlated with the magnitude of the study

~

between TAB and

CHD.

~

would suggest

An association between sex and study

sex mediates the relation between TAB and CHD.
Year of publication.

The year 1978 was chosen as a

point at which to divide the studies into two groups.
Studies published before or during 1978 were considered to
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be early studies and studies published after 1978 were
categorized as more recent studies.

This year was chosen

because it was the year of the NHLBI's review.

Presumably,

any influences over time occur because of historical trends.
Therefore, the time the data were collected would be a more
exact indicator of the history of the study.

Unfortunately,

many studies did not report this information so the year of
publication was chosen as the best available proxy.
The findings of some studies were reported in several
articles in which some were published before and others
after 1978.

In these cases, the study was classified as

occurring before 1978 because the earliest publication date
is nearest to the time the data were collected.
Unit of Analysis
One purpose of the current review was to determine why
some studies have reported null findings.

Presenting

results in smaller subunits (e.g., estimating different

~·s

for different age groups within a single study) would not be
consistent with this purpose.

That is, identifying

differences produced by different subpopulations is not the
purpose of the current research.

Therefore,

were not

~·s

estimated for subgroups within a single study.

A total of

61 independent studies were included in the current review.
When summing across

~·s,

only the results of

independent studies were combined.

When a single study

reported more than one result, several decision rules were
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used to decide which

~

should be used for the meta-analysis.

First, previous research (Booth-Kewley and Friedman, 1987)
has established that the

~·s

between TAB and CHO and between

TAB and MI are similar.

Therefore, the results of studies

that used either of these two disease outcomes were
combined.

Only the

~

for the CHO outcome was used to avoid

double weighting in studies that reported results for both
CHO and MI.

In addition, only the results of the longest

follow-up period were used to calculate a

~

to insure that

the results of prospective studies were not double weighted.
Some of the analyses presented in the current review
examined the association between study characteristics
(e.g., study design) and number of positive (statistically
significant) versus null findings.

A few studies were

difficult to code for these analyses because a

~

could be

calculated for more than one study characteristic.

For

example, a study might be weighted twice if the results were
reported for both prospective and cross-sectional designs or
for two different measures of TAB.

In these cases, the

study was treated as one finding if the results were the
same for all study characteristics; otherwise, the study was
not used in the analysis.

The exclusion of studies did not

lead to missing data problems.

No more than three studies

were excluded from an analysis because the studies reported
mixed results.
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Testing for the Presence of DBS Bias
DBS bias is defined as occurring when the range of
disease in the sample has been restricted to subjects with
moderate to severe disease (Miller et al., 1988).

Thus, DBS

bias is present in studies in which completely healthy
individuals are not selected for study.

DBS bias produces

null findings to the extent that the level of disease in the
high risk comparison group is equivalent to the level of
disease in the diseased group.

As the spectrum of disease

across the two groups narrows, the percentage of Type A's in
the high risk comparison and diseased groups becomes
equivalent so there is no significant difference in the
percentage of Type A's found in these two groups.
There are two signs of DBS bias that researchers can
test for.

One would have evidence to suggest that DBS bias

has produced the null findings in high risk studies if these
signs are present.

One sign of DBS bias is a high

percentage of Type A's found in both the diseased and
comparison groups used in high risk studies and a low
percentage of Type A's found in healthy populations.

This

pattern of results would suggest more Type A's than Type B's
develop CHO.

However, this finding is obscured in high risk

studies in which all of the subjects have some CHO because a
high percentage of Type A's are found in both the high risk
comparison group and the diseased group in high risk
studies.
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A second way to test whether DBS bias may have produced
the low

~

in recurrent CHO studies is to determine if range

restriction can account for the reduced
studies.

The

~

~·s

found in these

obtained from recurrent CHO studies can be

considered to have two parts:

a part produced by range

restriction and a part not attributable to range restriction
(e.g., sampling variability, other biases).
formula that estimates the attenuation in

~

One can use a
that would occur

in a high risk study given a healthy population

~

and an

estimate of the percentage of the population that is
excluded from the study sample.

This formula is referred to

as a range restriction formula.

One can compare the

~

obtained from the range restriction formula with the actual
~

between TAB and CHO.

estimated and actual

~·s

A significant difference between the
would suggest that study

characteristics other than range restriction have
contributed to the small

~·s

found in high risk studies.

In

contrast, range restriction may have produced the smaller
~·s

found in high risk studies if the estimated results are

not significantly different from the actual results.
Testing for a higher percentage of Type A's in high
risk populations.

The binomial

~

test (for a discussion,

see Miller et al., 1988) was used in the current research to
determine whether significantly higher percentages of Type
A's were present in high risk populations than in healthy
populations.

The binomial

~

test requires an accurate
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estimate of the percentage of Type A's found in a healthy
population.

Therefore, a review of the literature was

conducted to obtain an accurate estimate.
Estimating the reduction in the magnitude of the r
produced by range restriction in recurrent CHD studies.
Alexander, Carson, Alliger and Barrett (1985) provide a
range restriction formula that can be used to estimate the
reduction in r in high risk studies4 •

The formula is used

in the current research to estimate the reduction in r
between TAB and CHD in a recurrent CHD study from the r
obtained in a healthy population study.
The range restriction formula requires a healthy
population estimate of the r between a disease and a risk
factor.

Unfortunately, no estimates of the r between TAB

and CAD from healthy population studies are available.
Therefore, no range restriction formulas were calculated for
angiography studies.

For recurrent CHD studies, the range

restriction formula requires an estimate of the percentage
of healthy subjects who are expected to incur a MI in the
future and an estimate of the r between TAB and MI found in
a healthy population study.

The estimates used for the

range restriction formula for the recurrent CHD studies were
from the healthy population prospective results of the WCGS
(4.3% MI rate and r

= .33).
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Distinguishing between DBS bias and other subject
selection biases.
other types of
1988).

DBS bias can often be distinguished from

s~bject

selection biases (Miller et al.,

One would suspect that DBS bias has produced null

findings when the percentages of Type A's across diseased
and comparison groups only vary with whether the study used
a high risk or healthy population design.

Alternatively,

one would have evidence that other subject selection biases
are present if the study
selected.

~·s

vary with the way subjects were

For example, high risk studies have selected

subjects with CHO by four different methods:

(a) selection

on the basis of their risk factor status, (b) selection by
the results of an angiography in which subjects were
diagnosed as having clinically significant CAD, (c)
selection because an individual developed CHO during the
course of a prospective study or (d) selection because one
worked in a company participating in a study.
The percentage of Type A's found in these high risk
studies would be expected to vary with these different
subjects selection methods if subject selection biases other
than DBS bias have produced the null findings in high risk
studies.

To determine the extent to which subject selection

biases may have reduced the relation between TAB and CHO,
the current research examined whether the prevalence of TAB
and the

~

between TAB and CHO varied with the method used to

select subjects.

One would have evidence that DBS bias has
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produced the null findings in high risk studies if the

~

between TAB and CHO and the prevalence of TAB varies with
whether the study was high risk or healthy population.
Other subject selection biases may be present if the

~

between TAB and CHO and the prevalence of TAB varies with
how the subjects were selected.

40

RESULTS
study Characteristics Associated with the Trend Towards Null
Findings
The results of the current research support BoothKewley and Friedman's (1987) finding of a significant trend
towards null findings in research on TAB and CHD.

As

indicated by the Fisher exact test, studies included in the
current review were significantly more likely to report
positive findings before 1979 for both the SI (p<.05) and
self-report measures (p<.005).

There were four times as

many studies reporting null findings after 1978 for studies
that assessed TAB by the SI and eight times as many studies
reporting null findings for studies that used self-report
measures.
Table 3 illustrates that three types of studies have
been associated with null findings: (a) high risk studies,
(b) studies that used self-report measures and (c) studies
that used fatal MI as a disease criterion.

All three of

these types of studies have been conducted more frequently
after 1978.

Thus, all three types of studies have

contributed to the trend towards null findings.
High risk studies.

High risk studies accounted for the

majority of the null findings.

Among the 39 independent

studies that reported null findings, 24 were high risk
studies.

High risk studies had significantly more null

findings--by the Fisher exact test--than healthy population
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Table 3
summary of the Characteristics Studies with Null Findings

HIGH RISK

HEALTHY

SI STUDIES SELF-REPORT

BOTH SELF-REPORT

FATAL Ml

UNKNOWN

INADEQUATE
SAMPLE SIZE

AND HIGH RISK

Nl.lllber of studies with
null findings

16

8

84

30

89

100

81

79

87

100

17

8

2

Percentage of studies
that reported null
findings

Percentage of studies
published after 1978

Notes.

100

100

The total nl.lllber of independent studies that reported more null results than positive

results was 30.
study design.

HIGH RISK SI STUDIES are studies that assessed TAB by the SI and used a high risk
HEALTHY POPULATION SELF-REPORT studies used a self-report measure and a healthy

population study design.

Two studies clearly used inadequate sample sizes.

(1985) only examined 18 subjects with CHO.

Appels and Mulder

Keefe, Castell and Blumenthal (1986) had a total sample

size of 25.

The UNKNOWN collJ!n represents one study that did not fall into any of the other

categories.

INADEQUATE SAMPLE SIZE and UNKNOWN could be any studies in the sample.

percentage of studies that reported null findings is left blank.

Therefore, the

The UNKNOWN study was a case-

control by Wielgosz, Wielgosz, Biro, Nichols, MacWilliam, and Haney (1988) that used the SI to
assess TAB.
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studies for all studies that assessed TAB by the SI (p <
.005) and by self-report measures (p < .005).

Overall, 24

independent high risk studies reported null results, three
reported mixed results and only four reported positive
results.
There was a trend towards null findings for all of the
different types of high risk studies.

Before 1979, three

out of four angiography studies reported positive results.
After 1978, only one study reported a positive result, three
reported mixed results for different measures of TAB and 15
reported null results.

Similarly, only one of the five

recurrent CHD studies were conducted before 1979.

One study

conducted after 1978 reported mixed results and the other
studies reported null results.

Finally, two studies that

selected subjects on the basis of their traditional risk
factor status also reported null findings and were published
after 1978.

In sum, most high risk studies were conducted

after 1978 and reported null results.
Healthy population studies that assessed TAB by the SI.
In contrast to high risk studies, healthy population studies
that used the SI were associated with positive findings.
For studies that used the SI, six of eight reported positive
findings.

Although there has been an increase in the number

of high risk studies in recent studies, there has not been
an increase in the number of healthy population studies that
assessed TAB by the SI in recent years.
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Only two

prospective studies used the SI to assess TAB since 1978.
In one of these studies {Appels & Mulder, 1985), the sample
size was clearly. insufficient {only 18 subjects with CHD)
and the study reported null results.

Thus, only one study

in recent years has assessed whether the SI is a predictor
of CAD and this study reported a positive result.
Studies that assessed TAB by self-report measures.

The

use of self-report measures in healthy population studies
has also contributed to null findings in recent years.

For

studies that used self-report measures, 15 of 26 studies
reported positive findings, three studies reported mixed
results, and eight reported null findings. Only three of
eight healthy population prospective studies that assessed
TAB by self-report measures since 1978 reported positive
results.
There has been an increase in the number of studies
using self-report measures in recent years.

For studies

that used self-report measures, 19 of 26 healthy population
studies were conducted after 1978.
Table 4 presents the number of studies, percentage of
significant findings, WMR's, IVI's, confidence intervals
{CI's) for the WMR's and the study
design and measure of TAB.

H for

each type of study

The table illustrates how study

design and measures of TAB are related to the percentage of
significant findings and the magnitude of the WMR.
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Table 4
Findings for Each

T~

of Studv Design

Prospective

Cross-sectional

High risk Healthy population High risk
Recurrent Population

Healthy population

Angiography Case-

CHO

Population

Control
Studies That Used the SI

# of

studies

4(4)

3(3)

13(11)

5(5)

1(1)

" of
positive
findings

0

67

23

80

100

.33
.013
.31-.35

.13
.168
.09- .17

.35
.126
.31-.39

.31
.000
.28-,34

4,298

2,348

114R
IVI
Cl

.12
.001
.06- .18

Total
N

954

605

3,524

Studies That Used the JAS
# of

studies

4(4)

7(4)

9(5)

7(7)

7(5)

" of
positive
findings

2S

43

22

86

86

.00
.027
- .OS- .OS

.26
.006
.20-.32

.07
.004
.OS-.09

1,367

933

114R
IVI
Cl

.02
.013
- .02- .06

.04

.003
.03-.0S

Total
N

2,308

18,330
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10, 101

Table 4 continued
Prospective

Cross-sectional

High risk Healthy population High risk
Recurrent

Population

Healthy population

Angiography Case-

Population

Control

CHO

Studies That Used Other Self-report Measures
# of

0

studies
% of
positive
findings

8(3)

4(3)

3(3)

40

13

75

33

.00
.018
-.03-.03

.21
.031
.12- .30

.19
.001
.17-.21

3,395

481

.03
.015
.01-.05

WMR
!VI
Cl
Total
N

Notes.

5(4)

16,085

13,668

# of studies = the nunber in parentheses represents the nunber of reports in which an

could be calculated.

r

The nunber not in parentheses is the total nunber of studies; % of positive

findings = the percentage of studies that reported a significant positive association between TAB
and CHO; !VI =percentage of variation in

r across studies that cannot be attributed to sampling

error; Cl = 95% confidence interval; Total N = total nunber of subjects used to estimate the WMR's.
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A small

~

between self-report measures of TAB and CHD

appears to have produced some of the null findings.
prospective studies that assessed TAB by self-report
measures were consistently associated with small
WMR's for these studies varied from .04 to
Table 4 labeled "WMR").

.oo

~·s.

The

(see row in

Many healthy population studies

(30%; see Table 3) found null results.

The reason for the

larger WMR's in the cross-sectional healthy population
studies is not clear5 •
Studies that used fatal MI as a criterion.

Table 5

presents the results for studies that used fatal MI as a
disease criterion.

All eight studies found no statistically

significant association between TAB and fatal MI.
of these studies, the
negative direction.

~

In most

between TAB and fatal MI was in the

Thus, using fatal MI as a criterion

produces results that are markedly different from studies
using other disease criteria.

The use of fatal MI has

contributed to the trend towards null findings because all
eight studies were published after 1978.
Evidence of DBS bias in High Risk studies
Evidence of smaller r's in high risk studies.
would expect smaller

~·s

One

in high risk studies than have been

found in healthy population studies if DBS bias is present
because DBS bias is a type of range restriction that may
attenuate

~·s

in high risk studies.

In fact, the

~

between

TAB and CHD does appear to be larger in healthy population
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Table 5
studies that Used Fatal MI as a Criterion

Measure

Author

Year

N

r

Healthy Population Prospective Studies
SI

Ragland

1988b

3, 154

.09

Bortner

Mann

1987

7,214

-.07

FRHM

Eaker

1988

337

-.27

High Risk Prospective Studies

Notes.

SI

De Leo

1985

68

-.21

SI

Shekelle

1985

3, 110

.03

SI

Ragland

1988a

231

- .34

JAS

Dimsdale

1981

189

JAS

Case

1985

516

Unique

Ruberman

1984

2,320

-.11

Measure = the measure of TAB used; Author = the first author of the article; Year = the year

of publication of the article reporting the study findings; N =study sample size; FRHM =The
Framingham Type A scale; Unique = a measure of TAB was used that has not been used in any other
study.

WMR's are not reported because of the substantial inter-study variation that is probably

produced by the use of different measures of TAB.
cases in their sample.

All four were Type A.

Appels and Mulder (1985) reported four fatal Ml

Koskenvuo, Kaprio, Langinvainio and Romo (1983)

reported an analysis of fatal MI in which only three subjects had fatal MI.
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studies than high risk studies.

There is a moderate r

between the SI and CHO in healthy population studies (see
row in Table 4 labeled "WMR"; prospective healthy population

=

.33; case control = .35; cross-sectional population =

.31).

These WMR's are among the largest

Table 4.

~·s

presented in

In contrast, the WMR's for high risk studies that

assessed TAB by the SI were smaller (recurrent CHO= .12;
angiography= .13).

A similar pattern of smaller

~·sis

found in studies that used self-report measures (see Table
4).

Evidence of a lower percentage of Type A's in healthy

populations.

One would expect a lower percentage of Type

A's in healthy populations than among individuals with CHO
if TAB is associated with CHO.

Table 6 presents the

percentage of Type A's found in all healthy population
studies that assessed TAB by the SI and that reported
results in sufficient detail to estimate the prevalence of
TAB.

The results in Table 6 indicate that the percentage of

Type A's found among healthy middle-aged American men is
46%±1% (H

=

5,383; IVI = .001).

Evidence for the influence of culture.

TAB is

supposedly a product of the aggressive American lifestyle
(Rosenman, 1986).

In support of this hypothesis, the

percentage of Type A's found in populations outside the
United States appears to be somewhat lower.

In these

studies, the percentage of Type A's varied from 27% to 52%
and was generally lower than the studies conducted in the
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united states (see Table 6 column labeled"% of Type A's").
similarly, the percentage of Type A's in high risk studies
conducted outside the United States (60%±3%; N=l,111; IVI =
.016) was lower than in studies conducted in the United
states (see Table 7).
In spite of these base rate differences, the

~·s

between TAB and CHO in countries that were conducted outside
the United States are similar in magnitude to those studies
that were conducted in the United States.

The IVI's for the

WMR's presented in Table 4 are generally very small
suggesting that there is little inter-cultural variation in
WMR's.

For example, there appears to be no substantial

difference in the

~

between healthy population studies

conducted in the United States that assessed TAB by the SI
(WMR = .32±.02; N=3,443; IVI = .009) and studies conducted
outside the United States (WMR = .36±.03; N=l,460; IVI =
• 004) •
In sum, cultural differences among subjects do not
appear to influence the magnitude of the
CHO.

~

between TAB and

Thus, WMR's are reported for all countries combined.

However, culture is related to the prevalence of TAB.
Therefore, prevalence rates for the SI are only reported for
studies conducted in the United States in the current paper.
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Table 6
The Prevalence of Type A's in Healthy Population Studies that Assessed TAB by the SI

Studies Conducted in the United States
X of Type A's(N)

Author

Year

Keith+

1964

31(69)

Caffrey

1969

42(1521)

Rosenman

1975

49(2897)

Bryne

1985

46(582)

Moss

1986

47(314)

Studies Conducted outside the United States

Notes.

x of Type A's(N)

Author

Year

Country

Kittel

1978

38(726)

Belgi1.111

Verhagen+

1980

43(58)

Netherlands

Orth-Gomer+ 1980

27(48)

Sweden

Appels

1987

48(191)

Netherlands

Wielgosz+

1988

52(71)

Canada

Author = the first author of the article that reported the study findings;

Year = the year

of publication of the article reporting the study findings; X of Type A's(N) =the nl.lllber not in
parentheses indicates the percentage of Type A's and the nunber in parentheses indicates the nunber
of subjects the percentage estimate was based on; Country = the country in which the study was
conducted.

The weighted mean percentage of Type A's for studies conducted in the U.S.A. was 46X C,tf

= 5,383).

The weighted average prevalence of TAB for countries other than the United States was not

calculated because of substantial intra-study variation (IVI = .307).
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Table 7
percentase of Type A's Found in Hish Risk Studies

Author

Year Disease

X Type A's in

Country

criteria

--Diseased Comparison
Group

Group

Angiography Studies
Blunenthal

1978

TOTCI

80(64)*

44(78)

U.S.A.

Krantz

1981

TOTCI

78(49)*

71 (34)

U.S.A.

Dembrowski

198S

TOTCI

U.S.A

Blunenthal

198S

TOTCI

U.S.A

Frank

1978

>SOX

80(118)* 4S(29)

U.S.A

Krantz

1979

>SOX

67(4S)*

U.S.A.

Dimsdale

1979

>SOX

64(87)*

Scherwitz

1983

>SOX

U.S.A.

Willi ams

1980

>75X

79(28S)* 67(139)* U.S.A.

Arrowood

1982

>75X

U.S.A.

Siegman

1987

>75X

U.S.A.

Blunenthal

1987

>75X

Murphy

198S

Langeluddecke 1988

60(92)*

62(16)

76(21)

U.S.A.

U.S.A.
U.S.A.

>SOX

46(40S)

52

41(114)

Australia

Table 7 continued

Recurrent CHO studies
Rosenman

1967

CHO

70(33)*

67(170)* U.S.A.

Krantz

1979

CAD

nc13>

62(32)*

Rechnitzer

1983

Ml

76(79)*

70(539)* Canada

De Leo

1986

Ml

44(88)

43(51)

U.S.A.

Italy

Studies that selected on the basis of risk factor status

~·

Shekel le

1985

Ml

Bel maker

1976

CHO

73(129)* 74(2991)* U.S.A.
68(34)*

70(44)*

U.S.A.

* = the test of the hypothesis that the percentage of Type A's is greater than 47% is

statistically significant by the

binomial~

test that is corrected for continuity and adjusted by

the Bonferroni criteria (Individual alpha = .05/12 = .004); Author = the first author on the article
that reported the study findings;
= increase in severity of CAD;

Year= the year of publication of the findings of the study; CAD

>SOX and >75% are CAD scoring methods in which only subjects with no

occluded coronary arteries greater than 50 or 75% occlusion are classified as healthy; TOTCI is
another CAD scoring method (Blumenthal et al., 1985);

X of Type A's= the nunbers not in

parentheses indicate the percentage of Type A's and the riuii>ers inside the parentheses indicate the
riuii>er of subjects used to estimate the percentages of Type A's.

53

Evidence of a higher prevalence of TAB in high risk
g_omparison and diseased groups.

One would expect that a

higher percentage of Type A's would be found in both the
high risk comparison and diseased groups in high risk
studies than in healthy populations if DBS bias has produced
the null findings in high risk studies.

The findings of the

current research support this hypothesis.
Table 7 presents the percentages of Type A's in the
diseased groups and the high risk comparison groups in high
risk studies.

In addition, Table 7 displays the binomial

z

test of the difference in the percentage of Type A's found
in healthy population studies versus diseased comparison
groups.

A statistically significant binomial

indicated by a

"*"

in Table 7.

z

test is

The upper bound of the

confidence interval (47%) of the percentage of Type A's
found in the healthy population studies was used as an
estimate for the binomial
research.

z

tests conducted in the current

The test of the hypothesis that the percentage of

Type A's is greater than 47% is statistically significant by
the binomial

z

test was corrected for continuity and

adjusted by the Bonferroni criteria (Individual alpha =
.05/12

=

.004).

For studies conducted in the United States, a
significantly higher percentage of Type A's than the 47%
healthy population estimate were found in all but one study.
A small sample size appears to be the reason for the lack a
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statistical significance in the one study {H = 13).

The

percentage of Type A's found in this study is similar to the
percentages found in the other studies.

Thus, this study

may also have had a statistically significant result if a
larger sample size was used.

In addition, the high risk

comparison groups with sufficient sample sizes to obtain
significant results had significantly more Type A's than
found in healthy populations.
The percentage of Type A's found in the high risk
comparison groups is similar to that found in the diseased
groups.

For the 1,349 subjects with diagnosed CHD or CAD in

the studies conducted in the United States, 70% {±2%;
IVI=.006) were Type A's; a much higher percentage of Type
A's than the 46% found in healthy populations.

For the high

risk comparison groups, the percentage of Type A's was
similar to the diseased groups varying from 62% to 76% {see
columns labeled"% Type A's Comparison Group").
Evidence of range restriction.
range restriction.

DBS bias is a type of

Thus, one would expect that range

restriction formulas could estimate the reduced

~·s

found in

recurrent CHD studies if in fact DBS bias has reduced
these studies.

The

~

~·s

in

calculated from the range restriction

formula is .14 for recurrent CHD studies that assessed TAB
by the SI.

To estimate the reduction in

~

in high risk

studies that used the JAS, the healthy population

~

between

the JAS and CHD was assumed to be .04; this is the WMR for
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all healthy population prospective studies (see Table 4).
The estimated

~

for studies that assessed TAB by the JAS is

.02.

Table 8 presents the expected

~·s

estimated from the

range restriction formula, the observed ~·s, the standard
error associated with the 95% confidence interval of the
observed

~·s

and the absolute value of the difference

between the expected and observed

~·s.

Recall that the

range restriction formulas used to derive the expected
only use information regarding the

~

~·s

found in healthy

populations and the percentage of healthy subjects that have
been excluded from the sample.

Thus, the range restriction

formula estimates the degree of range restriction that would
be expected in a high risk sample given that a certain
percentage of low risk subjects has been excluded from the
study sample.

Therefore, the restriction in range formula's

results is independent of the actual study findings.
differences between the expected and observed
are always smaller than the standard error.

~·s

The

in Table 8

That is, the

expected

~·s

are within the 95% confidence intervals of the

observed

~·s

in every study.

Thus, the expected

~·s

estimated from the range restriction formulas accurately
estimate the magnitude of the
recurrent CHO studies.

~

between TAB and CHO found in

These results support the hypothesis

that DBS bias has produced the reduction in
recurrent CHO studies.
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~

found in

Table 8
CQ!IP8rison of Observed r's between TAB and CHO in Recurrent CHO Studies with Expected r's

N Expected

Author

Observed Standard Absolute value

r

r

error

of the difference

Studies that assessed TAB by the SI
618

.14

.12

.08

.02

88

.14

.17

.21

.03

203

.14

.05

.14

.09

Weishted mean 909

.14

.11

Rechnitzer
De Leo
Rosenman

.03

Studies that assessed TAB by the JAS
Jenkins

98

.02

.07

.20

.05

2070

.02

.02

.04

0

70

.02

-.11

.24

-.13

Weighted mean 2238

.02

.02

Shekel le
Appels

Notes.

= the

N = s~le size; Expected r
r reported in the study;

= the

0

r estimated by the range restriction fornula; Observed r

Standard error

= the

95X confidence interval; Absolute value of the

difference = the absolute value of the difference between the expected and observed r.
results for the 8.5 year WCGS for the JAS were not presented in a manner in which an
estimated.

Follow-up

r could be

Therefore, the 4.5 year follow-up results by Jenkins et al. (1971) are reported in Table

8.

57

The base rates of MI in prospective studies of CHO
conducted in this review varied from 6.2% to 2.2%.

To test

whether the results were influenced by the 4.3% base rate
estimate used to calculate the expected

~

by the range

restriction formula, base rates from 10% to 1% were used to
calculate different expected
formulas.

No observed

any of the expected

~

~·s

from the range restriction

was significantly different from

~·s.

Thus, the findings for the range

restriction formulas appear to be robust with regards to the
estimate of the base rate of CHO that is used.
Evidence of selection biases.

One would expect the

prevalence of TAB to vary with the way subjects were
selected if selection biases have influenced research on TAB
and CHO.

The percentages of Type A's were similar across

all different subject selection methods for subjects with
CHO in the studies included in the current review.
were selected by four different methods:
the basis of risk factor status (72±7% ;
.065),

Subjects

(a) selection on

H = 163; IVI

~

(b) selection by the results of an angiography in

which subjects were diagnosed as having clinically
significant CAD (74±3%;

H = 740; IVI = O), (c) selection

because the individual developed CHO during the course of a
prospective study (69±6% ;

H=

257) and (d) selection

because one worked in a company participating in a study
(71±7%; li

=

113).
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The prevalence of TAB in healthy population comparison
groups is consistent across several different methods of
subject selection (see Table 6).

These studies selected

subjects from towns, factories, monasteries and hospital
wards that included patients without CHO.

The findings

suggest that the method used to select subjects does not
greatly influence the prevalence of TAB in research on TAB
and CHO.
In contrast, there was variation in the prevalence of
TAB across three different types of high risk comparison
groups:

(a) studies that selected subjects with the

traditional risk factors (74%±1%;

H = 3,035; IVI = O), (b)

studies that reported the results of the two earliest
angiography studies (44%± ;

H = 107 ; IVI = 0) and (c)

studies that reported the results of other high risk studies
(67%±4%;

H = 412 ; IVI = 0).

The two earliest angiography

studies used subject selection methods that are similar to
more recent studies.

Thus, subject selection methods cannot

account for the differences between these two studies and
later angiography studies.

However, there appears to be a

slight increase--74% versus 67%--in the percentage of Type
A's found in studies that select subjects on the basis of
their risk factor status.
The WMR's varied only with whether the sample was
healthy population (prospective healthy population = .33;
case control

=

.35; cross-sectional population
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=

.31) or

high risk (recurrent CHO= .12; angiography= .13).

The

IVI's for high risk and healthy population studies were all
low (see Table 4).

Thus, different methods of subject

selection other than the high risk versus healthy population
distinction do not appear to influence the prevalence of TAB
or the magnitude of the ~ between TAB and CHD6 •

Only the

two studies that selected subjects on the basis of their
risk factor status appear to have significantly more Type
A's in their high risk comparison groups than have been
found in other high risk comparison groups.
Evidence of a trend towards more DBS bias in
angiography studies.

Miller et al.

(1988) suggested that

screening procedures for diagnostic angiography have
improved in recent years so that fewer completely healthy
subjects have been selected for study.

Thus, there has been

an increase in the extent of CAD in the diseased comparison
groups in angiography studies in recent years.

Miller et

al. proposed that this restriction in range of CAD severity
has attenuated

~·s

between TAB and CAD in recent years.

In fact, the percentage of Type A's in the diseased
comparison group in angiography studies has increased.

The

earliest two angiography studies had percentages of Type A's
(45% and 44%; see Table 7) in their diseased comparison
groups that are similar to the percentages of Type A's that
have been found in healthy populations (see Table 5).

More

recent angiography studies have reported higher percentages
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of Type A's in their diseased comparison groups (see Table
7) •

The increase in the percentage of Type A's in the
diseased comparison groups has apparently produced the null
findings in angiography studies.

Only three studies in

Table 7 reported positive findings.

The two angiography

studies published in the United States before 1979 reported
positive results.

Only one other study (Williams et al.,

1980; H=424) achieved a statistically significant result by
using a larger sample size than other angiography studies.
In further support of the hypothesis that screening
procedures have improved, the angiography study

~·s

are

inversely correlated with year of publication within each
type of CAD scoring method (see Table 9).

The IVI for

angiography studies that assessed TAB by the SI is large
(.168) because of a trend towards smaller

~·s

in recent

years.
Finally, one would expect the percentage of
angiography patients with diagnosed CAD would increase if
diagnostic screening procedures have improved.

In fact, the

percentage of individuals diagnosed as having CAD in the
sample is nearly perfectly correlated with the year of
publication (see Table 9).

In fact, the Spearman rank

~·s

between the percentage of individuals with CAD and year of
publication is 1.0 for the studies using the TOTCI method
and the >75% occlusion scoring methods.
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Only two findings were inconsistent.

First, Krantz

found slightly fewer patients with CAD and a slightly higher
correlation between the SI and CAD than Dimsdale did a year
earlier (see Table 9).
small sample sizes.

Both studies were associated with

Therefore, the discrepancy may simply

be the result of sampling error.

Second, Langeluddecke

found a lower percentage of subjects with CAD.

The lower

percentage of patients with CHO found in this study may have
been the result of a lower prevalence of CAD in Australia.
There appears to be no relation between sex and the
magnitude of

the~

between TAB and CAD (see Table 8).

However, an insufficient number of studies other than
angiography studies have included women.

Therefore, the

current research could not determine whether the magnitude
of the relationship between TAB and CHO is influenced by
subject sex for studies that did not use angiography as a
disease criteria.
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Table 9
Year of Publication, X Ill and r in Angiography Studies that Assessed TAB by the SI

Year

x ill

r

X female

Blllllenthal

1978

45

.57

44

Krantz

1981

59

.14

8

Dembrowski

1985

69

.09

25

Blllllenthal

1985

73

-.09

31

Frank

1978

80

.55

16

Dimsdale

1979

84

.03

0

Krantz

1981

78

.07

0

Scherwitz

1983

>85

.03

0

Langeluddecke

1988

78

.08

21

Author

TOTCI Scoring Method

>SOX Occlusion Scoring Method
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Table 9 continued

-------------------------------------------------------------------------Author

X female

Year

X i LL

Blunenthal 1975

51

.67

44

Williams

1980

70

.25

28

Arrowood

1982

Siegman

1987

78

-.01

26

Blunenthal 1987

82

-.29

24

r

>75X Occlusion Scoring Method

Notes.

Author = the first author of the article that reported study findings;

publication of the study;

Year = the year of

X ill = the nuit>er of patients that were diagnosed as having significant

CAD; X females= the percentage of women in the sa...,Le;.

The r's reported in this table vary

slightly from Miller et al.'s (1988) report that reported adjusted r's.
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DISCUSSION OF STUDY FINDINGS
Research on TAB and CHO has been fraught with many
confusing and contradictory results.

The purpose of the

current quantitative review was to identify the study
characteristics that have contributed to the trend towards
null findings.

Three study characteristics--high risk study

design, use of self-report measures and use of fatal MI as a
disease criterion--were found to be associated with null
findings.

The current research documented that the

increased use of these types of studies in recent years has
contributed to the trend towards null findings.
In addition, the current review found several results
that converge to suggest that DBS bias has produced the null
findings in high risk studies.

First, the percentage of

Type A's was high in both the diseased comparison and
diseased groups.

Second, the prevalence of TAB in patients

with CHO was significantly higher than found in healthy
populations.

Finally, range restriction formulas accurately

estimated the actual correlations found in recurrent CHO
studies.
Other subject selection biases do not appear to offer a
plausible alternative explanation for the higher percentages
of Type A's found among subjects with CHO.

One would

suspect that the percentage of Type A's found in the study
sample would vary with the way subjects were selected into
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the study if other subject selection biases influence this
area of research.

However, the correlation between TAB and

CHO was consistent across studies that selected subjects
using a variety of methods.

Therefore, the results of the

current research suggest that the magnitude of the
correlation between TAB and CHO is not greatly influenced by
the methods used to recruit subjects with the exception of
the high risk versus healthy comparison group distinction.
Reasons for the Trend Towards Null Findings
Increased use of recurrent CHO studies.

Recurrent CHO

studies have only recently become popular; in the early
1970's, researchers reasoned that recurrent CHO studies were
more cost effective than healthy population prospective
studies.

They arrived at this conclusion because they

believed that recurrent CHO studies with higher base rates
of disease permitted smaller sample sizes (e.g., Sondik,
Brown & Silvers, 1974; The Multiple Risk Factor Intervention
Trial; MRFIT group, 1977) than healthy population studies.
These researchers reasoned that smaller sample sizes could
be used in recurrent CHO studies because higher base rates
increase the statistical power of a study.

Unfortunately,

these researchers failed to recognize that recurrent CHO
studies increase the base rate at the cost of greater range
restriction.

The results of the current research strongly

suggest that increasing the base rate by using high risk
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subjects is by no means a cost-effective or methodologically
sound strategy for research on CHO.
Increase in extent of CAD in angiography patients.

A

number of recent angiography studies have failed to find a
relationship between TAB and CAD.
suggested one possible explanation.

Miller et al.

(1988)

As expertise has

increased in screening procedures for selecting patients for
diagnostic angiography, the likelihood has decreased for a
healthy person to be scheduled for an angiography.
Therefore, recent angiography studies have not selected
healthy subjects for study and so DBS bias has attenuated
the correlation between TAB and CHO in recent years.

In

support of this hypothesis, the correlation between CAD and
the traditional risk factors (Fried & Pearson, 1987), and
CAD and TAB (Miller et al., 1988 and the current review) has
decreased in recent years.

In addition, the percentage of

Type A's in recent studies has been similar to that found in
patients with CHO.
Increased use of self-report measures.

Since the

National Heart, Blood and Lung Institute (1978) declared
that TAB was a risk factor for CHO, many CHO researchers
began to use indicators of TAB in their studies.

Perhaps in

an effort to reduce costs and save time, self-report
measures have been favored over the SI.

Unfortunately,

self-report measures of TAB have a low correlation with CHO.
Thus, many studies have found null results and the trend
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towards using self-report measures has contributed to the
trend towards null findings.
The use of fatal MI as a disease criterion.

In recent

years, the use of fatal MI as a disease criterion has always
led to null results.

There are a number of potential

explanations for these findings.

For example, some

researchers (e.g., Correspondence. 1988) have criticized the
reliability of death certificate information used as an
indicator of fatal MI in many studies.

Thus, the

reliability of the disease criterion is one potential
explanation for the null findings.
Two other possible explanations are worth mentioning.
Perhaps TAB may be less predictive of fatal MI because fatal
MI occurs most frequently in older subjects whose TAB status
has been altered by lifestyle changes accompanying
retirement or a prior history of MI (age bias).

Second,

there are two types of fatal MI's: sudden death and
nonsudden death.

Perhaps TAB is only predictive of one of

these types of fatal MI (Brackett & Powell, 1988).
The MRFIT Study.

The results of the MRFIT (Shekelle,

Hulley et al., 1985) are important to consider because the
MRFIT has been claimed by many to be the largest and most
sophisticated study to examine the relationship between TAB
and CHO in recent years.

MRFIT selected subjects on the

basis of their traditional risk factor status.

The

percentage of Type A's among individuals who remained
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healthy throughout the MRFIT was higher than any of the
healthy population studies and very similar to that found in
patients with a prior history of CHO.
One possible explanation for the higher percentage of
Type A's in the MRFIT study is that TAB is positively
correlated with the traditional risk factors that were used
to select subjects for the MRFIT.

Although previous

research suggests there is no simple linear relationship
between TAB and the traditional risk factors (see BoothKewley & Friedman, 1987), a nonlinear or multivariate
relationship may exist.
The findings of the Belgian Heart Disease Prevention
Project (Kittel, 1986) are also supportive of this
hypothesis.

This study was a successful intervention

designed to prevent CHO by reducing individuals' levels of
risk on the traditional risk factors.

This study found a

strong relationship between TAB and CHO in the control group
and no relationship in the treatment group after treatment.
Thus, the intervention appears to have altered the
relationship between TAB and CHO in some unknown way.

In

addition, only one other study that selected subjects on the
basis of their risk factor status (Belmaker, Pollin, Jenkins

& Brensike, 1976) found significantly more Type A's in the
diseased comparison group.
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Suggestions for Future Research
Healthy population studies are required to obtain
accurate estimates of the percentage of Type A's found in
healthy samples stratified by the other risk factors for
CHD.

Although healthy population estimates are available

for the SI, only one study (Moss et al., 1986) has used
representative sampling techniques.

Such studies are

required to assess the magnitude of the relation between TAB
and CHD, and TAB and the traditional risk factors.
Future healthy population prospective studies that
assess TAB by the SI would be useful for validating the
results of the WCGS.

At present, only three prospective

studies have assessed TAB by the SI.
Future research to control for and confirm that DBS
bias is a problem in high risk studies requires researchers
to use continuous indicators of disease severity and TAB
(Knaus et al., 1984; Miller et al., 1988).

By using

continuous indicators, researchers can demonstrate how the
relation between TAB and CHD is influenced by limiting the
range of CHD to only individuals with severe disease (e.g.,
Fried & Pearson, 1987).
There are other advantages to using continuous
measures.
variables.

categorization reduces associations between
Thus, the association between TAB and CHD is

underestimated when dichotomous variables are used.

The

artifactual categorization of TAB and CHD is also a problem
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because optimal categorization can vary from study to study
(Rorer et al., 1966).

Therefore, categorization leads to

arbitrary changes in the magnitude of the association
between TAB and CHD across different studies.

The

development and use of continuous measures of TAB (e.g.,
Friedman et al., 1986; Knaus et al., 1984) is an important
area for future research.
Another measurement issue is the development of selfreport measures of TAB.

The current research suggests that

self-report measures of TAB are not highly correlated with
CHD.

The development of more valid self-report measures of

TAB to is another area for future research.
The presence of age and sex bias could not be
adequately tested in the current research because most
previous research has been conducted on middle aged men.

To

understand how the relationship between TAB and CHD is
influenced by age and sex requires studies that examine
women and individuals at different ages.
Finally, future research is required to understand why
there appears to be a relationship between TAB and CHO.

One

possibly suggested by the current research is that TAB may
be more closely associated with the traditional risk factors
than has been suspected.

Another question is why TAB does

not appear to be predictive of fatal MI.
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POTENTIAL APPLICATIONS OF THE OT MODEL TO FUTURE RESEARCH
The DT model can be used to define other biases that
may influence the relationship between TAB and CHO.

The

following section of this dissertation describes how the DT
model can be used to define another type of spectrum bias
referred to as mortality bias.

In addition, this section

discusses suggestions for how the DT model can be applied to
future research on TAB and CHO.
Mortality Bias in Cross-Sectional High Risk Studies
Mortality bias reduces the degree of statistical
association between TAB and CHO in a similar manner to DBS
bias.

For DBS bias, healthy observations are excluded from

the study sample and this reduces the specificity.
Mortality bias occurs when the sensitivity is reduced by
patient mortality (Miller et al., 1988).

Similar to the

reduction in specificity produced by DBS bias, the decrease
in sensitivity produced by mortality bias attenuates risk
ratios.
Figure l(c) can be used to illustrate how mortality
The line labeled Q'' in

bias reduces the sensitivity.

Figure l(c) is an exclusion point and indicates where
patients' CHO is sufficiently severe that a fatal MI has
occurred.

In Figure l(c), more Type A's are located in the

section of the distribution where fatal MI's occur.
exclusion of subjects with fatal MI decreases the
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The

sensitivity because more Type A's incur a fatal MI than Type
B's in the extreme diseased end of the continuum (see Figure
l(c)).

This loss of Type A's to mortality decreases the

percentage of Type A's in the diseased group in the study
sample.

The sensitivity decreases as the number of

individuals who have incurred a fatal MI before the
beginning of the study increases.
Typically, mortality bias is not as great a problem as
DBS ·bias because fewer subjects incur fatal disease than
remain healthy.

For example, 96% of the subjects did not

incur an initial MI and so were excluded from the recurrent
CHD study in the first 8.5 years of the WCGS study.

In

contrast, the percentage of fatal MI's in the WCGS that
would not be included in future follow-up studies was only
1%.

That is, only 1% of the sample was excluded that could

produce mortality bias.

The percentage of fatal MI's in the

22 year follow-up period was not substantially greater--only
7% (Ragland & Brand, 1988b).

Recurrent CHD studies exclude

all subjects who have not incurred an MI.

Therefore, the

spectrum of disease in these studies is limited to only the
most severely diseased subjects.

In comparison to mortality

bias, a substantially higher percentage of subjects are
excluded from studies that produce DBS bias.

Therefore,

mortality bias is typically not as great a problem as DBS
bias.

Yet, many researchers have argued that mortality bias

may have influenced their results while the possibility of
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DBS bias has been ignored (Feinstein, 1986; Ransohoff &
Feinstein, 1978).
Implications of the DT Model for Future Research
Research to determine what biases are important.
Methodological concerns have been dominated by a concern
with selection biases (Sackett, 1979).

For example,

researchers have consistently suggested that contradictory
findings in research on TAB and CHO have been produced by
problems associated with selection biases (Matthews, 1988).
One purpose of the current paper is to suggest that spectrum
biases also deserve consideration.
Quantitative reviews (e.g., Miller et al., 1988) can
be used to determine the impact of various biases within a
research domain (Einarson, Leeder, & Koren, 1988).

These

reviews can be used to determine which biases have a great
influence on the magnitude of the correlation between TAB
and CHD and which biases may not be important.
Interpretation of results.

Quantitative reviews can be

useful for determining the relative importance of risk
factors.

These are many well known reasons why a researcher

may not find an association between a risk factor and a
disease (e.g., inadequate statistical power, unreliability
in measurement).

Spectrum and selection biases are

potential explanations for null findings that should be
carefully considered before researchers are certain there is
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no substantial association between a risk factor and a
disease.
Detecting mortality bias.

Researchers have not tested

the extent to which mortality bias may have influenced the
magnitude of the relationship between TAB and CHO.

One

could determine the extent to which mortality bias is a
problem by testing whether the sensitivity between TAB and
CHO decreases in populations in which a higher percentage of
individuals have incurred a fatal MI.

That is, researchers

should compare the sensitivities across different subgroups
of individuals or individuals in different studies with
varying mortality rates (Ransohoff & Feinstein, 1978).

One

would have evidence of mortality bias if the sensitivities
decrease in samples with higher mortality rates.
Investigating other types of spectrum biases.

This

dissertation only discussed two types of spectrum biases
that may contribute to confusing and contradictory findings
in epidemiological research--DBS bias and mortality bias.
The DT model can be used to describe other types of spectrum
biases.

Similarly, there is no reason to consider only

cases where the spectrum of disease is reduced.

Spectrum

biases may be concerned with any aspect of the pathology,
clinical features or co-morbidity of the study sample
(Ransohoff & Feinstein, 1978).
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Research to assess the prevalence of risk factors.
Establishing healthy population estimates of the specificity
of a risk factor for different populations is an important
aspect of research because healthy population estimates are
useful for ascertaining the true magnitude of the
association between a risk factor and a disease across the
entire spectrum of the disease.
Planning sample sizes for future research.

Researchers

who aspire to conduct high risk studies should attempt to
estimate a priori the extent to which DBS bias attenuates
risk ratios in their high risk studies.

Appendix B of this

manuscript presents a derivation of a formula that can be
used for calculating the expected reduction in the RR and/or
the odds ratio for a high risk studies.

Researchers should

use this formula to calculate expected risk ratios and to
estimate the sample size required to obtain a statistically
significant result in high risk studies.
The expected power analyses may be quite discouraging
to those interested in conducting high risk studies.

In

many cases, the estimated reduction in risk can be
substantial.

For example, 2.3% of all subjects in the WCGS

at the 4.5 year follow-up were found to have a symptomatic
MI, and the RR reported in the healthy population
prospective study was 2.5 (see Table 2).

Among those

subjects who incurred an initial MI, 16% incurred a
recurrent CHD.

Applying these estimates to the formulas
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presented in Appendix B, the estimated RR is 1.2 for the
WCGS recurrent CHO results.

This result is quite similar to

the actual results (RR= 1.1) of the recurrent CHO of the
WCGS.
The difference between the healthy population findings
and the high risk study findings is substantial; varying
from 2.5 to 1.1.

This difference is almost entirely

predicted by a formula that estimates the degree to which
DBS bias reduces statistical associations in high risk
studies.

The research reported in the results section of

this dissertation found that similar DBS bias formulas for
~·s

predicted the small associations between TAB and CHO

reported in other recurrent CHO studies.

All of these

findings suggest that DBS bias is a serious problem in
research on TAB and CHO.

DBS bias may also be a problem in

other research domains.
One can estimate the sample sizes for the healthy
population and high risk studies by calculating the minimum
sample size required to obtain a chi-squared value that
would be significant at some level of significance (e.g., R
< .05).

These power analyses are useful for understanding

how much of an increase in sample size is required to obtain
a statistically significant result in high risk studies.
The estimated sample size required to obtain a statistically
significant result from the recurrent CHO study using an
estimated RR of 1.2 is 2,378.

In comparison, the minimum
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required sample size to obtain a statistically significant
result in the healthy population study that reported a RR of
2.s would be 1,092.

These results suggest much larger

sample sizes may be required for research conducted in
recurrent CHO populations than for heathy population
studies.

These findings are consistent with the research

presented in the results section of this dissertation.
These results suggested that DBS attenuates correlations in
recurrent CHO studies.
Another possibility before conducting new studies that
researchers should consider is to estimate the influence of
DBS bias in previous high risk studies.

For example, biased

specificities for TAB found in high risk studies could have
been replaced with a healthy population estimate of the
specificity and new adjusted odds ratios can be estimated
(Miller et al., 1988).

The healthy population estimate of

the specificity can be obtained by a review of the
literature of healthy population studies such as the one
conducted in this dissertation.

The difference between the

actual and adjusted odds ratio can be used as an indicator
of the extent to which DBS bias has attenuated associations
between TAB and CHO in previous high risk studies 7 •
Using previous research from other sciences.

Although

the concept of spectrum bias has only recently been
discussed in epidemiology (Feinstein, 1986; Miller et al.,
1988; Philbrick, Horwitz, Feinstein, Langou & Chandler,
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1982; Ransohoff & Feinstein, 1978), spectrum bias has a long
history in other scientific endeavors.

There are several

relevant areas of research the interested reader may
consult.

In industrial psychology (Lord & Novick, 1968;

Thorndike, 1949) and statistics (Little & Rubin, 1987;
Rydberg, 1963), spectrum biases have been referred to as
range restriction.

In economics, the term sample selection

bias has been used (Heckman, 1979).
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APPENDIX B

ESTIMATING REDUCTION IN RISK
This appendix illustrates a technique for estimating
the reduction in risk produced by DBS bias in a high risk
study from the results of healthy population studies.

All

one requires are values for the statistical parameters that
describe the. DT model presented in Figure l(b).

These

parameters are (a) the probability of possessing the risk
factor (e.g., being a Type A) in the study sample (b) the
magnitude of the g', (c) the location of Q and Q', and (d)
the shape of the distributions of the risk factors.

For the

equations presented in the current paper, the shape of the
frequency distributions for different values of the risk
factor are assumed to be normal and symmetric with respect
to disease status.
To illustrate the estimation procedure, an example from
research on TAB and CHO is used.

The RR associated with

recurrent CHO is obtained from an estimate of the
probability of incurring a MI in a healthy individual
(p(d)).

The probability of recurrent CHO in the future for

a healthy individual (the probability of recurrent disease
in a healthy individual= p(rdh)) is described by the
following equation
p(rdh) = p(d)p(rd)

(1)

where p(rd) equals the probability of recurrent CHO in
a sample of individuals with a history of MI.

95

In some

cases, an estimate of p(rdh) may be obtained directly from
the results of a healthy population prospective study.

In

other cases, estimates of p(rd} and (d} can be obtained from
prior research and these values can be used to calculate
p(rdh).
The next step is to obtain

~

scores that satisfy the

following equations.

zAh - Zeh

=

gI

(2)

w1p (rdAh} + w2p (rd8h} = p (rdh}

( 3)

where "zh" equals the z score associated with p(rdh), the A
and B subscripts indicate Type A and Type B behavior and "w"
indicates the weights associated with the probability of
being Type A or Type B in the healthy population study
sample.

The 'A' and 'B' subscripts for the A and B

distributions indicate which distribution--Type A or B--the
z score or probability is estimated from.

For example,

p(rdAh) indicates the probability of recurrent CHD in
healthy Type A's.

Equation (2) is the standard equation for

the effect size g' (Glass, McGraw, & Smith, 1981).

Equation

(3) indicates that the sum of the number of Type A's and B's
who develop recurrent CHD equals p(rdh).
The simplest way to calculate the zh scores is to use a
standard

~

score conversion table.

One simply finds the

pair of zh scores with probability values that sum to p(rdh)
and that satisfy equation (2).
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The zh scores can be used to

estimate the RR.

The formula for the RR is

p ( zAh) p ( Ze) /p ( ZA) p (Zeh)

(4)

where each .P(Z_) equals the probability value
associated with a z score, and a z without a "h" sign equals
the z score associated with the probability that a healthy
individual will incur a MI.

The formula for the odds ratio

is
(p(ZA)-p(zAh)) (p(rdeh)/(p(Ze)-p(zeh)) (ZAh))

(5)

Furthermore,
p ( zAh) / (p (Zeh) + p ( zAh) )

(6)

equals the sensitivity and
(p ( Ze) -p (Zeh))/ (p ( Ze)

(7)

equals the specificity.
The following is an example of how one can use the
preceding equations to estimate the RR between TAB and CHO
in the recurrent CHO of the WCGS from the healthy population
results.

In order to estimate the RR, one first obtains an

estimate of p(rd).

For example, the WCGS reported that

approximately 2.3% of the subjects developed symptomatic
MI's over the 4.5 year follow-up period.

Thus, p(rd) equals

2.3%.
Second, one obtains the

~

scores associated with the

percentage of Type A's and B's who develop CHO from the
healthy population results.

The

~

scores associated with

the percentages of Type A's and B's that incur a MI can be
obtained from a standard score conversion table.
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These

z

scores would both be located at£ in Figure l(b).

One~

score is associated with the Type B distribution and one

~

score is associated with the Type A distribution.
Subtracting the Type B
provides an estimate of

~

~

score from the Type A

g'.

For example,

the~

score
score

associated with the percentage of Type A's that incurred a
~

MI in the WCGS is 1.85.

The

percentage of Type B's.

The difference between the Type A

and B

~

scores is 0.37.

score is 2.22 for the

Therefore, the

g' for the WCGS is

0.37.
The next step is to

obtain~

scores for£'.

For

recurrent CHO studies, g' is the point at which individuals
develop recurrent CHO.

To obtain these estimates, one only

requires an estimate of p(rd').

In the case of the WCGS,

the recurrent CHO rate was 16%.

Using equations 2 and 3,

the estimated result for the recurrent CHO study is 1.2.
Table 2 presents the results for the actual and
estimated recurrent CHO study of the WCGS.

In no cases are

the estimated results significantly different from actual
results.

The only discrepancy between the estimated and

actual results occurs in the sensitivity (this also accounts
for the lower

g').

For a discussion of possible reasons why

the sensitivity in high risk studies is lower than the
estimates, see the section of the current paper entitled age
bias.
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The range restriction formulas derived in the current
paper are based on the assumption that the Type A and B
distributions are symmetric with respect to CHO status and
that the relationship between TAB and CHO is linear.

In

many cases, this may be an unreasonable assumption.

The

need for range restriction formulas based on less
restrictive distributional assumptions is area of future
research.

Research using quasi-continuous measures of TAB

and CHO would be useful to determine that the relationship
between TAB and CHO is linear and bivariate normal.
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Endnotes

1.

Most research has treated CHO as a dichotomous variable

(e.g., MI versus no MI, angina versus no angina).

The

current research defines CHO as a continuum in which MI or
angina are discrete points along a spectrum of disease
severity.

Many researchers (e.g., Knaus, Wagner & Draper,

1984; Miller, Turner, Tindale & Posavac, 1988) have noted
that defining CHO as a continuous variable is a useful way
of conceptualizing CHO.

When CHO is conceptualized as

occurring along a continuum, one can describe high risk
studies as a sample in which only individuals from the
diseased range of CHO are selected for study.
2.

Previous research suggests the relationship between TAB

and CHO is linear (Booth-Kewley and Friedman, 1987) and that
the distributions of Type A's and B's are normally
distributed (Kittel et al., 1978).

However, the

distribution of TAB with respect to CHO status remains
unknown because researchers have relied on statistical
analyses that treated CHO and TAB as dichotomous variables.
3.

Hedges and Olkin (1985) have recommended correcting

~·s

for unreliability to obtain a more accurate estimate of the
theoretical relation between the variables of interest.
Previous research (Booth-Kewley & Friedman, 1987) has
addressed this question.

Correction for unreliability was
100

not undertaken in the current research because the focus was
to identify study characteristics that are associated with
positive and null findings.
A chi-squared test (see Hedges & Olkin, 1985) was used
to determine if the amount of inter-study variance not
attributable to sampling variability as indicated by the IVI
was statistically significant.
almost always significant.

The chi-squared test was

This finding is not surprising

considering the large sizes examined in the current
research.

However, the magnitude of the IVI in most cases

suggests that the actual percentage of variance attributable
to inter-study variation is quite small.

Therefore, the

results of the chi-squared tests are not reported.
4.

The range restriction formula that is presented in

Alexander et al.

(1985) is
_, 1/2

E(r) =

~I

Where E(r) equals the expected value of

~,

rxy is the

value or r observed in the healthy population study, and X
and Y are equal to
X = 1 - (h2/phi 2 ) + (h/phi) (Zxc>
2

Y = 1 - (r xy) (h2/phi 2 ) + r 2xy) (h/phi) (Zxc>
Where phi is the selection ratio, h is the height of
the normal curve on X corresponding to the observed phi, and
Zxc is the standard score cutoff point on X for phi.
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5.

The substantial inter-study variation (IVI

=

.132) in

the case control studies that assessed TAB by the SI was
produced entirely by one study (Wielgosz et al., 1988;
.04).

~

= -

The WMR for case-control studies that assessed TAB by

the SI excluding this study (WMR = .41,

N =505; IVI = .009)

is much higher and consistent with the results for case
control studies using self-report measures of TAB (see Table
2) •

The large WMR's associated with case control studies
are inconsistent with the results of other more
methodologically rigorous designs.

This finding is

consistent with other meta-analyses (Einarson, Leeder &
Koren, 1988).

Therefore, the results of case-control

studies should probably be treated with more caution than
other type of designs.
6.

Another frequently mentioned explanation for the null

findings in high risk studies has been that a person's TAB
status may change after incurring CHD.

However, this

hypothesis appears to be incorrect because the prevalence of
TAB in subjects with CHD is similar in both prospective and
cross-sectional studies.
For the studies reported in the current review,
subjects' TAB status was assessed soon after the coronary
event.

Therefore, TAB status may change after the first few

months following a MI.
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7.

Unfortunately, replacing healthy population estimates of

the sensitivity or specificity to correct for biased
estimates may frequently be impractical.

One reason is that

healthy population estimates of individuals with similar
characteristics to the diseased sample are often
unavailable.

Furthermore, all the characteristics that may

be important are often unknown.

Thus, the omitted variable

problem may produce misleading results when adjusted risk
ratios are used.
Another problem with replacing a study sample estimate
with a healthy population estimate is that this reduces the
study design to essentially a case-control design even if
the original design was prospective.
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